{"transactions":[{"id":694698,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-06T21:11:40.000Z","date":"2026-08-05","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.9816,"value":9816.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.972 to $0.9898, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1993551,"source":{"system":"sec-edgar","filing":"0001493152-26-036396","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315226036396/ownership.xml","form_type":"4"}},{"id":696305,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-05T20:10:26.000Z","date":"2026-08-03","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":0.9412,"value":70590.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.87 to $0.9499, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1983551,"source":{"system":"sec-edgar","filing":"0001493152-26-036169","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315226036169/ownership.xml","form_type":"4"}},{"id":751451,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-03T20:10:45.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":235000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options vest in four equal annual installments, with the first such installment to vest on June 3, 2027, subject in each case to continued employment with the Issuer on the applicable vesting date and subject to potential accelerated vesting upon a Change in Control or termination for Cause, as such terms are defined in the 2025 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options vest in four equal annual installments, with the first such installment to vest on June 3, 2027, subject in each case to continued employment with the Issuer on the applicable vesting date and subject to potential accelerated vesting upon a Change in Control or termination for Cause, as such terms are defined in the 2025 Equity Incentive Plan."}],"balance_after":235000,"derivative":{"exercise_price":1.12,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":235000},"source":{"system":"sec-edgar","filing":"0001493152-26-027054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226027054/ownership.xml","form_type":"4"}},{"id":882724,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T21:10:11.000Z","date":"2026-02-24","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.9976,"value":19952.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.98 to $1.00, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1908551,"source":{"system":"sec-edgar","filing":"0001493152-26-008039","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315226008039/ownership.xml","form_type":"4"}},{"id":915077,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T21:10:05.000Z","date":"2026-02-06","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.9456,"value":47280.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.8899 to $0.9880, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1888551,"source":{"system":"sec-edgar","filing":"0001493152-26-005773","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315226005773/ownership.xml","form_type":"4"}},{"id":940001,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":36007,"kind":"person","name":"PFENNIGER RICHARD C JR","position":1,"cik":"0001200796","reported_name":"PFENNIGER RICHARD C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-01-13T21:10:14.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":16410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."}],"balance_after":16410,"derivative":{"exercise_price":1.1,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":16410},"source":{"system":"sec-edgar","filing":"0001493152-26-002042","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226002042/ownership.xml","form_type":"4"}},{"id":940000,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69437,"kind":"person","name":"Lee Sam","position":1,"cik":"0001602074","reported_name":"Lee Sam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Co-CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-01-13T21:10:09.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":49229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date."}],"balance_after":49229,"derivative":{"exercise_price":1.1,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":49229},"source":{"system":"sec-edgar","filing":"0001493152-26-002038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226002038/ownership.xml","form_type":"4"}},{"id":940302,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":11868,"kind":"person","name":"Hassan Fred","position":1,"cik":"0001110744","reported_name":"Hassan Fred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-01-13T21:10:08.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":16410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."}],"balance_after":16410,"derivative":{"exercise_price":1.1,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":16410},"source":{"system":"sec-edgar","filing":"0001493152-26-002037","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110744/000149315226002037/ownership.xml","form_type":"4"}},{"id":939999,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-01-13T21:10:06.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":49229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date."}],"balance_after":49229,"derivative":{"exercise_price":1.1,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":49229},"source":{"system":"sec-edgar","filing":"0001493152-26-002036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226002036/ownership.xml","form_type":"4"}},{"id":940386,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-01-13T21:10:05.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":24615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."}],"balance_after":24615,"derivative":{"exercise_price":1.1,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":24615},"source":{"system":"sec-edgar","filing":"0001493152-26-002035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315226002035/ownership.xml","form_type":"4"}},{"id":939997,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69435,"kind":"person","name":"Japour Anthony J","position":1,"cik":"0001773088","reported_name":"Japour Anthony J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-01-13T21:10:03.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":16410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."}],"balance_after":16410,"derivative":{"exercise_price":1.1,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":16410},"source":{"system":"sec-edgar","filing":"0001493152-26-002034","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226002034/ownership.xml","form_type":"4"}},{"id":939998,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-01-13T21:10:01.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":16410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."}],"balance_after":16410,"derivative":{"exercise_price":1.1,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":16410},"source":{"system":"sec-edgar","filing":"0001493152-26-002033","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226002033/ownership.xml","form_type":"4"}},{"id":940020,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69439,"kind":"person","name":"Kornberg Roger D.","position":1,"cik":"0001444532","reported_name":"Kornberg Roger D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-01-13T17:03:55.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":24615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date."}],"balance_after":24615,"derivative":{"exercise_price":1.1,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":24615},"source":{"system":"sec-edgar","filing":"0001683168-26-000263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444532/000168316826000263/ownership.xml","form_type":"4"}},{"id":955763,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-02T21:10:19.000Z","date":"2025-12-31","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.9455,"value":47275.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions ranging from $0.9370 to $0.9519, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the preceding sentence."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1838551,"source":{"system":"sec-edgar","filing":"0001493152-26-000114","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315226000114/ownership.xml","form_type":"4"}},{"id":956782,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-31T21:10:17.000Z","date":"2025-12-30","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.9655,"value":19310.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions ranging from $0.9635 to $0.9700, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the preceding sentence."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1788551,"source":{"system":"sec-edgar","filing":"0001493152-25-029796","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315225029796/ownership.xml","form_type":"4"}},{"id":958995,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T14:24:10.000Z","date":"2025-12-26","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0.9736,"value":38944.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 for December 24, 2025 is a weighted average price. These securities were sold in multiple transactions ranging from $0.9641 to $0.9803, inclusive. The price reported in Column 4 for December 26, 2025 is a weighted average price. These securities were sold in multiple transactions ranging from $0.9596 to $0.9837, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the preceding sentence."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1768551,"source":{"system":"sec-edgar","filing":"0001493152-25-029257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315225029257/ownership.xml","form_type":"4"}},{"id":958994,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T14:24:10.000Z","date":"2025-12-24","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":0.9703,"value":24257.5,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 for December 24, 2025 is a weighted average price. These securities were sold in multiple transactions ranging from $0.9641 to $0.9803, inclusive. The price reported in Column 4 for December 26, 2025 is a weighted average price. These securities were sold in multiple transactions ranging from $0.9596 to $0.9837, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the preceding sentence."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1728551,"source":{"system":"sec-edgar","filing":"0001493152-25-029257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315225029257/ownership.xml","form_type":"4"}},{"id":986370,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-28T14:00:02.000Z","date":"2025-11-26","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":0.99,"value":2475.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1703551,"source":{"system":"sec-edgar","filing":"0001493152-25-025314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315225025314/ownership.xml","form_type":"4"}},{"id":986369,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-28T14:00:02.000Z","date":"2025-11-26","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":1,"value":1500.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1701051,"source":{"system":"sec-edgar","filing":"0001493152-25-025314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315225025314/ownership.xml","form_type":"4"}},{"id":989291,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T01:17:04.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.9406,"value":18812.0,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions ranging from $0.937 to $0.943, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the preceding sentence."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1699551,"source":{"system":"sec-edgar","filing":"0001493152-25-025048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315225025048/ownership.xml","form_type":"4"}},{"id":1011601,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-10-30T20:15:25.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":719426,"price":1.39,"value":1000002.14,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":719426,"derivative":{"exercise_price":1.24,"expiration_date":"2028-01-28","underlying":"Common Stock","underlying_shares":719426},"source":{"system":"sec-edgar","filing":"0001493152-25-020222","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315225020222/ownership.xml","form_type":"4"}},{"id":1011600,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-30T20:15:25.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":359713,"price":1.39,"value":500001.07,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1679551,"source":{"system":"sec-edgar","filing":"0001493152-25-020222","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315225020222/ownership.xml","form_type":"4"}},{"id":1011503,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":11868,"kind":"person","name":"Hassan Fred","position":1,"cik":"0001110744","reported_name":"Hassan Fred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2025-10-30T20:15:23.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":719426,"price":1.39,"value":1000002.14,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."}],"balance_after":719426,"derivative":{"exercise_price":1.24,"expiration_date":"2028-01-28","underlying":"Common Stock","underlying_shares":719426},"source":{"system":"sec-edgar","filing":"0001493152-25-020221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110744/000149315225020221/ownership.xml","form_type":"4"}},{"id":1011502,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":11868,"kind":"person","name":"Hassan Fred","position":1,"cik":"0001110744","reported_name":"Hassan Fred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-30T20:15:23.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":359713,"price":1.39,"value":500001.07,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of common stock issuable upon vesting of restricted stock units."}],"balance_after":1383009,"source":{"system":"sec-edgar","filing":"0001493152-25-020221","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110744/000149315225020221/ownership.xml","form_type":"4"}},{"id":1011282,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":36007,"kind":"person","name":"PFENNIGER RICHARD C JR","position":1,"cik":"0001200796","reported_name":"PFENNIGER RICHARD C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2025-10-30T20:15:22.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":1.39,"value":55600.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."}],"balance_after":40000,"derivative":{"exercise_price":1.24,"expiration_date":"2028-01-28","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-25-020219","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225020219/ownership.xml","form_type":"4"}},{"id":1011281,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":36007,"kind":"person","name":"PFENNIGER RICHARD C JR","position":1,"cik":"0001200796","reported_name":"PFENNIGER RICHARD C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-30T20:15:22.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of common stock issuable upon vesting of restricted stock units."}],"balance_after":31400,"source":{"system":"sec-edgar","filing":"0001493152-25-020219","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225020219/ownership.xml","form_type":"4"}},{"id":1011279,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Warrants","published_at":"2025-10-30T20:15:20.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":7196,"price":1.39,"value":10002.44,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."}],"balance_after":7196,"derivative":{"exercise_price":1.24,"expiration_date":"2028-01-28","underlying":"Common Stock","underlying_shares":7196},"source":{"system":"sec-edgar","filing":"0001493152-25-020218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225020218/ownership.xml","form_type":"4"}},{"id":1011278,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Common Stock","published_at":"2025-10-30T20:15:20.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":3598,"price":1.39,"value":5001.22,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of common stock issuable upon vesting of restricted stock units."}],"balance_after":44167,"source":{"system":"sec-edgar","filing":"0001493152-25-020218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225020218/ownership.xml","form_type":"4"}},{"id":1387811,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T20:06:00.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":27100,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."}],"balance_after":27100,"source":{"system":"sec-edgar","filing":"0001493152-24-040901","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315224040901/ownership.xml","form_type":"4"}},{"id":1387509,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T20:05:58.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":18957,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."}],"balance_after":2660242,"source":{"system":"sec-edgar","filing":"0001493152-24-040905","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224040905/ownership.xml","form_type":"4"}},{"id":1387507,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69437,"kind":"person","name":"Lee Sam","position":1,"cik":"0001602074","reported_name":"Lee Sam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Co-CEO"}}],"security":"Common Stock","published_at":"2024-10-11T20:05:57.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."}],"balance_after":76355,"source":{"system":"sec-edgar","filing":"0001493152-24-040904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224040904/ownership.xml","form_type":"4"}},{"id":1387508,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":36007,"kind":"person","name":"PFENNIGER RICHARD C JR","position":1,"cik":"0001200796","reported_name":"PFENNIGER RICHARD C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T20:05:55.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":8067,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."}],"balance_after":11400,"source":{"system":"sec-edgar","filing":"0001493152-24-040902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224040902/ownership.xml","form_type":"4"}},{"id":1387506,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Common Stock","published_at":"2024-10-11T20:05:54.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."}],"balance_after":40569,"source":{"system":"sec-edgar","filing":"0001493152-24-040900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224040900/ownership.xml","form_type":"4"}},{"id":1387687,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":11868,"kind":"person","name":"Hassan Fred","position":1,"cik":"0001110744","reported_name":"Hassan Fred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T20:05:52.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":8067,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."}],"balance_after":1023296,"source":{"system":"sec-edgar","filing":"0001493152-24-040899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110744/000149315224040899/ownership.xml","form_type":"4"}},{"id":1387505,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69435,"kind":"person","name":"Japour Anthony J","position":1,"cik":"0001773088","reported_name":"Japour Anthony J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T20:05:52.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":14924,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."}],"balance_after":14924,"source":{"system":"sec-edgar","filing":"0001493152-24-040898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224040898/ownership.xml","form_type":"4"}},{"id":1387524,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69439,"kind":"person","name":"Kornberg Roger D.","position":1,"cik":"0001444532","reported_name":"Kornberg Roger D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T16:06:02.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":28109,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."}],"balance_after":28109,"source":{"system":"sec-edgar","filing":"0001493152-24-040903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444532/000149315224040903/ownership.xml","form_type":"4"}},{"id":1826142,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-20T20:05:32.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":19333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":19333,"derivative":{"exercise_price":2.67,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":19333},"source":{"system":"sec-edgar","filing":"0001493152-23-025086","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315223025086/ownership.xml","form_type":"4"}},{"id":1825673,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69435,"kind":"person","name":"Japour Anthony J","position":1,"cik":"0001773088","reported_name":"Japour Anthony J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-20T20:05:30.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":13567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":13567,"derivative":{"exercise_price":2.67,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":13567},"source":{"system":"sec-edgar","filing":"0001493152-23-025085","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223025085/ownership.xml","form_type":"4"}},{"id":1825672,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-20T20:05:28.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the \"Code\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 18, 2024 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to continued employment on each applicable vesting date."}],"balance_after":30000,"derivative":{"exercise_price":2.67,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-23-025084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223025084/ownership.xml","form_type":"4"}},{"id":1825670,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69437,"kind":"person","name":"Lee Sam","position":1,"cik":"0001602074","reported_name":"Lee Sam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Co-CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-20T20:05:24.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the \"Code\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 18, 2024 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to continued employment on each applicable vesting date."}],"balance_after":30000,"derivative":{"exercise_price":2.67,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-23-025082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223025082/ownership.xml","form_type":"4"}},{"id":1825671,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":36007,"kind":"person","name":"PFENNIGER RICHARD C JR","position":1,"cik":"0001200796","reported_name":"PFENNIGER RICHARD C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-20T20:05:21.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":7333,"derivative":{"exercise_price":2.67,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001493152-23-025081","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223025081/ownership.xml","form_type":"4"}},{"id":1826021,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":11868,"kind":"person","name":"Hassan Fred","position":1,"cik":"0001110744","reported_name":"Hassan Fred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-20T20:05:19.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":7333,"derivative":{"exercise_price":2.67,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001493152-23-025080","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110744/000149315223025080/ownership.xml","form_type":"4"}},{"id":1825669,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-20T20:05:17.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":17233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":17233,"derivative":{"exercise_price":2.67,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":17233},"source":{"system":"sec-edgar","filing":"0001493152-23-025078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223025078/ownership.xml","form_type":"4"}},{"id":1825714,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69439,"kind":"person","name":"Kornberg Roger D.","position":1,"cik":"0001444532","reported_name":"Kornberg Roger D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-20T16:05:26.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":24417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":24417,"derivative":{"exercise_price":2.67,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":24417},"source":{"system":"sec-edgar","filing":"0001493152-23-025083","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444532/000149315223025083/ownership.xml","form_type":"4"}},{"id":1924152,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72760,"kind":"organization","name":"Frost Gamma Investments Trust","position":2,"cik":"0001380896","reported_name":"Frost Gamma Investments Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-06T20:01:20.000Z","date":"2023-04-04","kind":"purchase","planned":false,"acquired":true,"shares":1015229,"price":1.97,"value":2000001.13,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in a private transaction with the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The amount of securities beneficially owned has been adjusted for the one-for-12 reverse stock split effective October 11, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by Frost Gamma Investments Trust, of which Phillip Frost, MD (the \"Reporting Person\") is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. The Reporting Person is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. The Reporting Person is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1319838,"source":{"system":"sec-edgar","filing":"0001493152-23-011239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315223011239/ownership.xml","form_type":"4"}},{"id":2195558,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69435,"kind":"person","name":"Japour Anthony J","position":1,"cik":"0001773088","reported_name":"Japour Anthony J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-08-03T20:51:21.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":148000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":148000,"derivative":{"exercise_price":0.42,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":148000},"source":{"system":"sec-edgar","filing":"0001493152-22-021187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315222021187/ownership.xml","form_type":"4"}},{"id":2195557,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co- Interim CEO and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-08-03T20:03:10.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the \"Code\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 25, 2023 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to continued employment on each applicable vesting date."}],"balance_after":300000,"derivative":{"exercise_price":0.42,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001493152-22-021150","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315222021150/ownership.xml","form_type":"4"}},{"id":2195554,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":36007,"kind":"person","name":"PFENNIGER RICHARD C JR","position":1,"cik":"0001200796","reported_name":"PFENNIGER RICHARD C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-08-03T20:03:08.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.42,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001493152-22-021151","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315222021151/ownership.xml","form_type":"4"}},{"id":2196501,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-08-03T20:03:04.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":220000,"derivative":{"exercise_price":0.42,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001493152-22-021152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315222021152/ownership.xml","form_type":"4"}},{"id":2195555,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-08-03T20:02:59.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":188000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":188000,"derivative":{"exercise_price":0.42,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":188000},"source":{"system":"sec-edgar","filing":"0001493152-22-021149","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315222021149/ownership.xml","form_type":"4"}},{"id":2195556,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69437,"kind":"person","name":"Lee Sam","position":1,"cik":"0001602074","reported_name":"Lee Sam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Co-Interim CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-08-03T20:02:43.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the \"Code\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 25, 2023 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to continued employment on each applicable vesting date."}],"balance_after":300000,"derivative":{"exercise_price":0.42,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001493152-22-021148","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315222021148/ownership.xml","form_type":"4"}},{"id":2195601,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69439,"kind":"person","name":"Kornberg Roger D.","position":1,"cik":"0001444532","reported_name":"Kornberg Roger D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-08-03T16:02:48.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":280000,"derivative":{"exercise_price":0.42,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001493152-22-021147","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444532/000149315222021147/ownership.xml","form_type":"4"}},{"id":2593473,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":36007,"kind":"person","name":"PFENNIGER RICHARD C JR","position":1,"cik":"0001200796","reported_name":"PFENNIGER RICHARD C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-23T22:02:05.000Z","date":"2021-08-20","kind":"purchase","acquired":true,"shares":40000,"price":1.028,"value":41120.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $1.02 to $1.03, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in the preceding sentence."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001493152-21-021048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221021048/ownership.xml","form_type":"4"}},{"id":2629139,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":36007,"kind":"person","name":"PFENNIGER RICHARD C JR","position":1,"cik":"0001200796","reported_name":"PFENNIGER RICHARD C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-20T20:06:09.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 16, 2022 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.11,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-21-017325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221017325/ownership.xml","form_type":"4"}},{"id":2629138,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-20T20:06:00.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the \"Code\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 16, 2022 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to continued employment on each applicable vesting date."}],"balance_after":250000,"derivative":{"exercise_price":1.11,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001493152-21-017327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221017327/ownership.xml","form_type":"4"}},{"id":2629137,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-20T20:05:54.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":88000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 16, 2022 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":88000,"derivative":{"exercise_price":1.11,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":88000},"source":{"system":"sec-edgar","filing":"0001493152-21-017326","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221017326/ownership.xml","form_type":"4"}},{"id":2629136,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69435,"kind":"person","name":"Japour Anthony J","position":1,"cik":"0001773088","reported_name":"Japour Anthony J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-20T20:05:38.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":74000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 16, 2022 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":74000,"derivative":{"exercise_price":1.11,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":74000},"source":{"system":"sec-edgar","filing":"0001493152-21-017324","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221017324/ownership.xml","form_type":"4"}},{"id":2629135,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69437,"kind":"person","name":"Lee Sam","position":1,"cik":"0001602074","reported_name":"Lee Sam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Co-Interim CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-20T20:05:35.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the \"Code\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 16, 2022 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to continued employment on each applicable vesting date."}],"balance_after":250000,"derivative":{"exercise_price":1.11,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001493152-21-017331","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221017331/ownership.xml","form_type":"4"}},{"id":2629569,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-20T20:05:30.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 16, 2022 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.11,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001493152-21-017330","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315221017330/ownership.xml","form_type":"4"}},{"id":2629177,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69439,"kind":"person","name":"Kornberg Roger D.","position":1,"cik":"0001444532","reported_name":"Kornberg Roger D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-20T16:06:04.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 16, 2022 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.11,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001493152-21-017328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444532/000149315221017328/ownership.xml","form_type":"4"}},{"id":2725009,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T22:00:16.000Z","date":"2021-05-04","kind":"sale","acquired":false,"shares":575000,"price":2.95,"value":1696250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.60 to $3.25, inclusive. The Reporting Person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":7674960,"source":{"system":"sec-edgar","filing":"0001493152-21-010669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221010669/ownership.xml","form_type":"4"}},{"id":2863034,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69437,"kind":"person","name":"Lee Sam","position":1,"cik":"0001602074","reported_name":"Lee Sam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-02-12T22:02:17.000Z","date":"2020-11-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as follows: 25,000 incentive stock options will vest on the one year anniversary of the grant date and the remaining 25,000 incentive stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on February 28, 2022, subject to continued employment on each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.3,"expiration_date":"2030-11-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-21-003686","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221003686/ownership.xml","form_type":"5"}},{"id":3100776,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69437,"kind":"person","name":"Lee Sam","position":1,"cik":"0001602074","reported_name":"Lee Sam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-24T22:52:15.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as follows: 50,000 stock options will vest on the one year anniversary of the grant date and the remaining 50,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021."}],"balance_after":100000,"derivative":{"exercise_price":1.33,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-20-011752","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315220011752/ownership.xml","form_type":"4"}},{"id":3100775,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69435,"kind":"person","name":"Japour Anthony J","position":1,"cik":"0001773088","reported_name":"Japour Anthony J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-24T22:50:33.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 28,000 stock options will vest on the one year anniversary of the grant date and the remaining 28,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021."}],"balance_after":56000,"derivative":{"exercise_price":1.33,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001493152-20-011751","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315220011751/ownership.xml","form_type":"4"}},{"id":3100773,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":148254,"kind":"person","name":"WILCOX GARY","position":1,"cik":"0001222257","reported_name":"WILCOX GARY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-24T22:12:33.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as follows: 100,000 stock options will vest on the one year anniversary of the grant date and the remaining 100,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021."}],"balance_after":200000,"derivative":{"exercise_price":1.33,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-20-011748","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315220011748/ownership.xml","form_type":"4"}},{"id":3100774,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-24T20:05:37.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as follows: 75,000 stock options will vest on the one year anniversary of the grant date and the remaining 75,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021."}],"balance_after":150000,"derivative":{"exercise_price":1.33,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001493152-20-011718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315220011718/ownership.xml","form_type":"4"}},{"id":3101250,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-24T20:05:31.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 25,000 stock options will vest on the one year anniversary of the grant date and the remaining 25,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021."}],"balance_after":50000,"derivative":{"exercise_price":1.33,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-20-011716","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315220011716/ownership.xml","form_type":"4"}},{"id":3100772,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-24T20:05:28.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 36,000 stock options will vest on the one year anniversary of the grant date and the remaining 36,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021."}],"balance_after":72000,"derivative":{"exercise_price":1.33,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001493152-20-011715","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315220011715/ownership.xml","form_type":"4"}},{"id":3100801,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69439,"kind":"person","name":"Kornberg Roger D.","position":1,"cik":"0001444532","reported_name":"Kornberg Roger D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-24T16:54:21.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 25,000 stock options will vest on the one year anniversary of the grant date and the remaining 25,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021."}],"balance_after":50000,"derivative":{"exercise_price":1.33,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-20-011730","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444532/000149315220011730/ownership.xml","form_type":"4"}},{"id":3386213,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-29T21:03:31.000Z","date":"2019-10-25","kind":"purchase","acquired":true,"shares":7906,"price":1.15,"value":9091.9,"ownership":{"direct":true},"balance_after":9257863,"source":{"system":"sec-edgar","filing":"0001493152-19-016105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315219016105/ownership.xml","form_type":"4"}},{"id":3386212,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-29T21:03:31.000Z","date":"2019-10-24","kind":"purchase","acquired":true,"shares":5094,"price":1.15,"value":5858.1,"ownership":{"direct":true},"balance_after":9249957,"source":{"system":"sec-edgar","filing":"0001493152-19-016105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315219016105/ownership.xml","form_type":"4"}},{"id":3386211,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-29T21:03:31.000Z","date":"2019-10-23","kind":"purchase","acquired":true,"shares":3935,"price":1.0386,"value":4086.891,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.965 to $1.08, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the footnote of this Form 4."}],"balance_after":9244863,"source":{"system":"sec-edgar","filing":"0001493152-19-016105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315219016105/ownership.xml","form_type":"4"}},{"id":3809005,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":79126,"kind":"person","name":"HSIAO JANE PH D","position":1,"cik":"0001188834","reported_name":"HSIAO JANE PH D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T20:56:30.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."}],"balance_after":50000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-18-013674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218013674/ownership.xml","form_type":"4"}},{"id":3809003,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69437,"kind":"person","name":"Lee Sam","position":1,"cik":"0001602074","reported_name":"Lee Sam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T20:52:36.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year."}],"balance_after":100000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-18-013671","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218013671/ownership.xml","form_type":"4"}},{"id":3809002,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T20:49:48.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."}],"balance_after":50000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-18-013669","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218013669/ownership.xml","form_type":"4"}},{"id":3809450,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T20:46:38.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."}],"balance_after":50000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-18-013667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315218013667/ownership.xml","form_type":"4"}},{"id":3809001,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T20:43:43.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."}],"balance_after":50000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-18-013665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218013665/ownership.xml","form_type":"4"}},{"id":3809000,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":163447,"kind":"person","name":"BLOCK DAVID S","position":1,"cik":"0001222646","reported_name":"BLOCK DAVID S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T13:29:44.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."}],"balance_after":50000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-18-013626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218013626/ownership.xml","form_type":"4"}},{"id":3808999,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":148254,"kind":"person","name":"WILCOX GARY","position":1,"cik":"0001222257","reported_name":"WILCOX GARY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T13:00:34.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year."}],"balance_after":200000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-18-013623","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218013623/ownership.xml","form_type":"4"}},{"id":3808998,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T13:00:31.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year."}],"balance_after":150000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001493152-18-013622","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218013622/ownership.xml","form_type":"4"}},{"id":3934621,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8% Convertible Note","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"exercise","acquired":false,"shares":263158,"price":500000,"value":131579000000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."}],"balance_after":263158,"derivative":{"exercise_price":1.9,"exercise_date":"2018-05-10","expiration_date":"2019-11-24","underlying":"Common Stock","underlying_shares":263158},"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3934620,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8% Convertible Note","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":263158,"price":500000,"value":131579000000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."},{"field":"security","element":"securityTitle","label":"F4","text":"In accordance with Rule 16b-3, in advance of the effectuation of the transactions reported, the issuer's board of directors approved an amendment to the convertible note held by the reporting person who is a director and 10% beneficial owner of the issuer. The amendment of the outstanding convertible note is reported as a cancellation of the \"old\" note and the grant of a replacement note."}],"balance_after":263158,"derivative":{"exercise_price":1.9,"exercise_date":"2018-05-10","expiration_date":"2019-11-24","underlying":"Common Stock","underlying_shares":263158},"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3934619,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8% Convertible Note","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"disposition_to_issuer","acquired":false,"shares":61728,"price":500000,"value":30864000000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."},{"field":"security","element":"securityTitle","label":"F4","text":"In accordance with Rule 16b-3, in advance of the effectuation of the transactions reported, the issuer's board of directors approved an amendment to the convertible note held by the reporting person who is a director and 10% beneficial owner of the issuer. The amendment of the outstanding convertible note is reported as a cancellation of the \"old\" note and the grant of a replacement note."}],"balance_after":61728,"derivative":{"exercise_price":8.1,"exercise_date":"2017-11-24","expiration_date":"2019-11-24","underlying":"Common Stock","underlying_shares":61728},"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3934618,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":10209,"price":1.9,"value":19397.1,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The reporting person was issued common stock in lieu of accrued interest owed in connection with the convertible note described in Table II."}],"balance_after":995593,"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3934617,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"exercise","acquired":true,"shares":263158,"price":1.9,"value":500000.2,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person was issued common stock in connection with the conversion of a convertible note, as amended, at $1.90 per share. See Table II for a description of the convertible note."}],"balance_after":985384,"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3944181,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-07T22:21:41.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":420737,"price":1.9,"value":799400.3,"ownership":{"direct":false,"nature":"By LP"},"balance_after":722226,"source":{"system":"sec-edgar","filing":"0001493152-18-006360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006360/form4.xml","form_type":"4"}},{"id":3944761,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":25984,"kind":"person","name":"FROST PHILLIP MD ET AL","position":1,"cik":"0000898860","reported_name":"FROST PHILLIP MD ET AL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72760,"kind":"organization","name":"Frost Gamma Investments Trust","position":2,"cik":"0001380896","reported_name":"Frost Gamma Investments Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Trustee"}}],"security":"Common Stock","published_at":"2018-05-07T21:06:02.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":105263,"price":1.9,"value":199999.7,"ownership":{"direct":false,"nature":"By Frost Gamma Investments Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in the Issuer's public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The amount of securities beneficially owned has been adjusted for the one for 30 reverse stock split effective January 24, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":3655265,"source":{"system":"sec-edgar","filing":"0001493152-18-006346","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898860/000149315218006346/form4.xml","form_type":"4"}},{"id":4137828,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"8% Convertible Note","published_at":"2017-12-08T22:42:19.000Z","date":"2017-11-24","kind":"grant","acquired":true,"shares":1851851,"price":500000,"value":925925500000.0,"ownership":{"direct":false,"nature":"By LP"},"balance_after":1851851,"derivative":{"exercise_price":0.27,"exercise_date":"2017-11-24","expiration_date":"2019-11-24","underlying":"Common Stock","underlying_shares":1851851},"source":{"system":"sec-edgar","filing":"0001493152-17-014433","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315217014433/form4.xml","form_type":"4"}},{"id":4257693,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2017-07-13T20:05:53.000Z","date":"2017-07-11","kind":"exercise","acquired":false,"shares":1706978,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.047,"exercise_date":"2014-11-25","expiration_date":"2018-01-02","underlying":"Common Stock","underlying_shares":1706978},"source":{"system":"sec-edgar","filing":"0001493152-17-007777","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315217007777/form4.xml","form_type":"4"}},{"id":4257692,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-13T20:05:53.000Z","date":"2017-07-11","kind":"exercise","acquired":true,"shares":1706978,"price":0.047,"value":80227.966,"ownership":{"direct":true},"balance_after":277227831,"source":{"system":"sec-edgar","filing":"0001493152-17-007777","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315217007777/form4.xml","form_type":"4"}},{"id":4346600,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-24T20:15:57.000Z","date":"2017-04-20","kind":"grant","acquired":true,"shares":4166667,"price":0.24,"value":1000000.08,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a purchase meeting the requirements of Rule 16b-3."}],"balance_after":9044717,"source":{"system":"sec-edgar","filing":"0001493152-17-004329","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315217004329/form4.xml","form_type":"4"}},{"id":4512405,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69437,"kind":"person","name":"Lee Sam","position":1,"cik":"0001602074","reported_name":"Lee Sam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Common Stock","published_at":"2016-12-23T21:05:11.000Z","date":"2016-12-23","kind":"sale","acquired":false,"shares":2200000,"price":0.44,"value":968000.0,"ownership":{"direct":true},"balance_after":13087847,"source":{"system":"sec-edgar","filing":"0001415889-16-007631","document":"form4-12232016_041201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000141588916007631/form4-12232016_041201.xml","form_type":"4"}},{"id":4610968,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":163447,"kind":"person","name":"BLOCK DAVID S","position":1,"cik":"0001222646","reported_name":"BLOCK DAVID S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-09-06T20:15:21.000Z","date":"2016-09-01","kind":"purchase","acquired":true,"shares":10000,"price":0.41,"value":4100.0,"ownership":{"direct":true},"balance_after":168696,"source":{"system":"sec-edgar","filing":"0001415889-16-007052","document":"form4-09062016_040909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000141588916007052/form4-09062016_040909.xml","form_type":"4"}},{"id":4610966,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-09-06T20:15:15.000Z","date":"2016-09-01","kind":"purchase","acquired":true,"shares":4878050,"price":0.41,"value":2000000.5,"ownership":{"direct":false,"nature":"By LLC"},"balance_after":4878050,"source":{"system":"sec-edgar","filing":"0001415889-16-007051","document":"form4-09062016_040905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000141588916007051/form4-09062016_040905.xml","form_type":"4"}},{"id":4610967,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":148254,"kind":"person","name":"WILCOX GARY","position":1,"cik":"0001222257","reported_name":"WILCOX GARY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CEO"}}],"security":"Common Stock","published_at":"2016-09-06T20:15:10.000Z","date":"2016-09-01","kind":"purchase","acquired":true,"shares":10000,"price":0.41,"value":4100.0,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":16948605,"source":{"system":"sec-edgar","filing":"0001415889-16-007050","document":"form4-09062016_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000141588916007050/form4-09062016_040901.xml","form_type":"4"}}]}